https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-september-9-2026/ 2026-09-09T20:54:18Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • September 9, 2026 2026-09-09T20:54:16Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-september-9-2026/ 2026-09-09T20:52:19Z Pharminent en Manufacturing Intelligence • Weekly Digest • September 9, 2026 2026-09-09T20:52:17Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-8-2026/ 2026-09-09T20:50:58Z Pharminent en Oncology Intelligence Digest • September 8, 2026 2026-09-09T20:50:56Z Blog https://pharminent.com/fda-names-permanent-cder-and-cber-directors-while-the-commissioners-post-awaits-confirmation/ 2026-09-09T19:48:36Z Pharminent en FDA Names Permanent CDER and CBER Directors While the Commissioner's Post Awaits Confirmation 2026-09-09T19:48:32Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-9-2026/ 2026-09-09T17:41:23Z Pharminent en Strategic News Watch • September 9, 2026 2026-09-09T17:41:21Z Blog https://pharminent.com/novartiss-del-desiran-misses-primary-endpoint-in-harbor-putting-the-12b-avidity-deal-under-scrutiny/ 2026-09-08T20:56:52Z Pharminent en Novartis's Del-Desiran Misses Primary Endpoint in HARBOR, Putting the $12B Avidity Deal Under Scrutiny 2026-09-08T20:09:35Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-8-2026/ 2026-09-08T19:07:19Z Pharminent en Strategic News Watch • September 8, 2026 2026-09-08T16:45:55Z Blog